Premium
Cardiovascular Properties of a Nitric Oxide Releasing Rofecoxib Analogue: Beneficial Anti‐hypertensive Activity and Enhanced Recovery in an Ischemic Reperfusion Injury Model
Author(s) -
Bhardwaj Atul,
Batchu Sri N.,
Kaur Jatinder,
Huang Zhangjian,
Seubert John M.,
Knaus Edward E.
Publication year - 2012
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201200234
Subject(s) - rofecoxib , medicine , pharmacophore , nitric oxide , blood pressure , pharmacology , anesthesia , reperfusion injury , ischemia , bioinformatics , cyclooxygenase , biochemistry , biology , enzyme , chemistry
Good news for the heart: The chronic use of rofecoxib causes adverse cardiovascular complications that prompted its withdrawal from the market. We recently modified rofecoxib into an NO‐releasing, potent anti‐inflammatory drug. Herein we describe the beneficial anti‐hypertensive effects of the NO‐releasing SO 2 NHOH COX‐2 pharmacophore on blood pressure and its ability to enhance recovery in a cardiac ischemic reperfusion injury model.